637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
0 activities
A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1 activities
A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria
1 activities
A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria
Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome
1 activities
Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome
Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
1 activities
Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome: A Propensity Score-Matched Retrospective Cohort Study Using Trinetx
1 activities
Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome: A Propensity Score-Matched Retrospective Cohort Study Using Trinetx
Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis
1 activities
Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis
Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations
1 activities
Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations
Development and Validation of a Biopsy-Free Scoring System for Screening Myelodysplastic Syndrome (MDS) and Associated Diseases in Cytopenic Patients
1 activities
Development and Validation of a Biopsy-Free Scoring System for Screening Myelodysplastic Syndrome (MDS) and Associated Diseases in Cytopenic Patients
Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
1 activities
Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
1 activities
ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles
1 activities
Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles
Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
1 activities
Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
1 activities
Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Impact of Mutational Landscape and CD47 Levels in the Magrolimab + Azacitidine Vs Placebo + Azacitidine Trial in Patients with Untreated Higher Risk Myelodysplastic Syndrome
1 activities
Impact of Mutational Landscape and CD47 Levels in the Magrolimab + Azacitidine Vs Placebo + Azacitidine Trial in Patients with Untreated Higher Risk Myelodysplastic Syndrome
Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
1 activities
Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
1 activities
Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyo...
1 activities
Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes
Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes
1 activities
Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes
Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
1 activities
Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
1 activities
Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
1 activities
Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study
1 activities
R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study
TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
1 activities
TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)
1 activities
Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)